AbbVie earlier

Early stage investorAbbott Biotech Ventures will start investing even earlier after parent company Abbott Laboratories (NYSE:ABT) splits in two, the firm's head of venture investment, Steven Kuemmerle, said at last week's C21 BioVentures conference in Napa, Calif.

Abbott Biotech Ventures will be part of AbbVie, a research-based pharmaceutical company. The other public company will house Abbott's generics, devices, diagnostic and nutritional businesses and retain Abbott's name. The split is expected to complete by year end...